Tag Archives: health

Valuation Dashboard: Healthcare – November 2015

Summary 4 key factors are reported across industries in the Healthcare sector. They give a valuation status of industries relative to their history. They give a reference for picking stocks in each industry. This article is part of a series giving a valuation dashboard by sector of companies in the S&P 500 index (NYSEARCA: SPY ). I follow up a certain number of fundamental factors for every sector, and compare them to historical averages. This article is going down at industry level in the GICS classification. It covers Healthcare. The choice of the fundamental ratios has been justified here and here . You can find in this article numbers that may be useful in a top-down approach. There is no analysis of individual stocks. A link to a list of individual stocks to consider is provided at the end. Methodology Four industry factors calculated by portfolio123 are extracted from the database: Price/Earnings (P/E), Price to sales (P/S), Price to free cash flow (P/FCF), Return on Equity (ROE). They are compared with their own historical averages “Avg”. The difference is measured in percentage for valuation ratios and in absolute for ROE, and named “D-xxx” if xxx is the factor’s name (for example D-P/E for price/earnings). The industry factors are proprietary data from the platform. The calculation aims at eliminating extreme values and size biases, which is necessary when going out of a large cap universe. These factors are not representative of capital-weighted indices. They are useful as reference values for picking stocks in an industry, not for ETF investors. Industry valuation table on 11/2/2015 The next table reports the 4 industry factors. For each factor, the next “Avg” column gives its average between January 1999 and October 2015, taken as an arbitrary reference of fair valuation. The next “D-xxx” column is the difference as explained above. So there are 3 columns for each ratio. P/E Avg D- P/E P/S Avg D- P/S P/FCF Avg D- P/FCF ROE Avg D-ROE HC Equipment&Supplies 34.5 27.18 -26.93% 4.12 3.18 -29.56% 45.64 30.51 -49.59% -20.09 -12.14 -7.95 HC Providers&Services 28.81 20.88 -37.98% 1.09 0.85 -28.24% 22.4 17.75 -26.20% 7.46 5.78 1.68 HC Technology* 56.41 56.13 -0.50% 4.11 3.39 -21.24% 32.35 35.77 9.56% -15.66 -6.2 -9.46 Biotechnology 47.8 39.78 -20.16% 50.92 29.01 -75.53% 41.33 43.74 5.51% -62.42 -64.42 2 Pharmaceuticals 32.96 26.26 -25.51% 12.28 8.25 -48.85% 29.82 32.55 8.39% -38.03 -30.3 -7.73 Life Sci. Tools&Services* 31.78 29.52 -7.66% 2.89 3.39 14.75% 32.39 27.28 -18.73% -8.87 -18.37 9.5 * Averages since 2006 Valuation The following charts give an idea of the current status of industries relative to their historical average. In all cases, the higher the better. Price/Earnings: Price/Sales: Price/Free Cash Flow: Quality Relative Momentum The next chart compares the price action of the SPDR Select Sector ETF (NYSEARCA: XLV ) with SPY (chart from freestockcharts.com). It also includes the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) and the SPDR S&P Pharmaceuticals ETF (NYSEARCA: XPH ) as industry benchmarks. (click to enlarge) Conclusion The broad Healthcare ETF has almost the same return as SPY in the last 6 months, with large discrepancies between industries. The biotechnology index has underperformed by about 4%, the pharmaceutical index by about 14%. Two series of news have hit the latter: political announcements on overpriced legacy drugs initiated by Mrs Clinton, then suspicions of unduly inflated sales involving specialty pharmacies. Valeant Pharmaceuticals Intl (NYSE: VRX ) is at the core of both cases, but the market has punished most names linked to generic drugs and specialty pharmaceutical products. As it includes hedge fund darlings, an ETF replicating famous managers’ holdings has also suffered from this: the AlphaClone Alternative Alpha ETF ( ALFA). Taking into account valuation charts above, all healthcare industries look overpriced. There is no contradiction with the positive value score reported for Healthcare in my latest S&P 500 sector dashboard . Here, mid and small caps have been added in calculations. It is a clue of a significant discrepancy between market cap segments inside the sector. The most influential valuation factor from a statistical point of view is P/FCF, and it is more optimistic than other ratios. It points out to a slight under-pricing in 3 industries: Healthcare Technology, Biotechnology and Pharmaceuticals. However, there may be quality stocks at a reasonable price in any industry. To check them out, you can compare individual fundamental factors to the industry factors provided in the table. As an example, a list of stocks in Healthcare beating their industry factors is provided on this page . If you want to stay informed of my updates, click the “Follow” tab at the top of this article. You can choose the “real-time” option if you want to be instantly notified.

Lipper Fund Flows: Gains For All Groups

By Patrick Keon Lipper’s fund macro-groups (including both mutual funds and exchange-traded funds [ETFs]) experienced aggregate net inflows for the fourth consecutive week-taking in over $56 billion of net new money during that time. The groups had positive flows of $24.8 billion for the fund-flows week ended Wednesday, October 28, paced by money market funds, which had net inflows of $15.7 billion. The other macro-groups all posted gains for the week as well; equity funds took in $8.4 billion of net new money, while taxable bond funds (+$432 million) and municipal bond funds (+$349 million) recorded more modest increases. The Dow Jones Industrial Average (+3.6%) and the S&P 500 Index (+3.5%) both posted strong performance numbers for the week. The indices were bolstered by improving economic data on the home front, stronger-than-expected corporate earnings reports from the technology sector, measures to ease global growth concerns, and the Federal Reserve’s leaving the window open to a possible interest rate hike before year-end. The week got off to a roaring start as both indices pocketed roughly 2.8% in combined gains during the first two trading days. Strong U.S. economic data and talk of more quantitative easing in Europe were the triggers on Day One. U.S. existing-home sales posted strong numbers for September (+4.7%), while new applications for unemployment benefits were at near-40-year lows. Across the pond, European Central Bank President Mario Draghi stated that the central bank may extend stimulus measures if global growth continues to be a concern. The rally continued on Day Two as tech companies Alphabet Inc., Microsoft Corp., and Amazon.com all posted stronger-than-expected earnings, while China announced a surprise interest rate cut (its sixth in less than a year) in an attempt to revive its slumping economy. The market experienced another bump on the last trading day of the week when the Fed hinted that the long-awaited interest rate increase may finally arrive in December. The Fed indicated that the global landscape will become less of a concern in December’s discussion, and the determining factors will be the next two monthly jobs reports (the Fed is looking for some additional improvement) and the inflation rate (for which the Fed has set a 2% target). The week’s net inflows for money market funds (+$15.7 billion) represented the fifth week in six of positive flows, which brought over $55 billion of net new money into the group. Institutional money market funds (+$11.6 billion) and institutional U.S. government money market funds (+$8.6 billion) were the two largest contributors to the week’s gains. Equity ETFs were responsible for the lion’s share of the net inflows (+$8.2 billion) for the equity group, while equity mutual funds contributed $221 million to the total. The SPDR S&P 500 Trust ETF (NYSEARCA: SPY ) (+$2.5 billion) and the Health Care Select Sector SPDR ETF (NYSEARCA: XLV ) (+$769 million ) had the two largest individual increases on the ETF side. For mutual funds-contradicting the trend we’ve seen all year-nondomestic equity funds had net outflows for the week (-$339 million), while domestic equity funds had positive net flows (+$560 million). Mutual funds were responsible for all the net inflows for taxable bond funds (+$660 million), while ETF products saw $228 million leave their coffers. Lipper’s High Yield Funds and Core Plus Bond Funds classifications (+$787 million and +$570 million, respectively) recorded the two largest net inflows on the mutual fund side. For ETFs, two Treasury products had the largest individual net outflows: The iShares 7-10 Year Treasury Bond ETF (NYSEARCA: IEF ) (-$602 million) and the iShares 3-7 Year Treasury Bond ETF (NYSEARCA: IEI ) (-$410 million). Municipal bond mutual funds took in $148 million of net new money-for their fourth consecutive week of positive flows. Funds in Lipper’s High Yield Municipal Bond Funds classification (+$181 million) accounted for all of the week’s net inflows.

The European Local Recovery: Introducing A New Index

By Jeremy Schwartz Earlier, we discussed how positive trends in the European economy showing domestic growth are leading the eurozone , while global trade has been one of the weak points. 1 We also discussed how our favorite leading indicators of the economy-both M1 growth and the European Commission’s Economic Sentiment Indicator-were showing positive signs that bode well for future trends in the local economy. 2 What could be a good way to position toward this local economic recovery? Creating an Index to Respond Strongly as Economic Conditions Improve At WisdomTree, we build innovative equity Indexes that offer the opportunity to express certain characteristics or have greater potential to respond to different economic trends. If an economic recovery in Europe is truly taking hold, we wanted to create an Index that best reflects these local economic conditions. WisdomTree thus created the WisdomTree Europe Local Recovery Index to reflect attributes of an improving domestic economy that is less reliant on the global export markets. Especially over the past five years, certain more defensive sectors of the MSCI EMU Index have exhibited lower correlation to changes in the economy and the leading indicator of activity, the European Commission’s Economic Sentiment Indicator. These defensive sectors thus may not offer the most representative exposures to improving economic conditions within the eurozone. Over the past five years, those same defensive sectors have exhibited lower betas when measured against the returns of the MSCI EMU Index. In times of turmoil or uncertainty, this could be a potentially positive attribute, but if an investor truly believes in the prospects for a eurozone economic recovery, these lower-beta defensive sectors are likely to be least responsive to a more positive growth environment. Defensive Sectors Less Correlated to Changes in Economic Activity and Sentiment (click to enlarge) Positioning in Cyclicals: No Defensives In positioning for local economy recovery, these data points lead us toward a preference for cyclical sectors over defensive sectors. Within the WisdomTree Europe Local Recovery Index, the Consumer Staples, Health Care, Telecommunication Services and Utilities sectors are not eligible for inclusion. Two important factors are driving allocations in the WisdomTree Europe Local Recovery Index: Stock Selection: In addition to the aforementioned sector screens, there is also a geographic revenue requirement to ensure a domestic European focus: constituents must derive more than 50% of their revenue from inside Europe, giving focus to what is happening within Europe and less sensitivity to the global growth outlook. Weighting: We also employ a weighting methodology to maximize sensitivity to improving economic conditions. This process tilts the weight toward stocks whose returns have been most correlated to changes in economic conditions, defined by the European Commission’s Economic Sentiment Indicator discussed above. This unique weighting methodology ranks stocks by their correlation to the Economic Sentiment Indicator and, using a smoothed weighting process, tilts weight from the traditional benchmark market capitalization weights toward stocks that are more responsive to changes in economic sentiment and activity. Formally, the weights are set by two factors: 25% according to their market capitalization percentages, and 75% according to how correlated each stock is to economic activity over the last five years (based on each stock’s returns and its relationship to the European Commission’s Economic Sentiment Indicator). Bottom Line 3 : Local Focus: WisdomTree Europe Local Recovery Index has nearly 70% of its weighted average revenue coming from within Europe. Opposite of WisdomTree Europe Hedged Equity Index: This is a distinctly complementary approach to that employed by the WisdomTree Europe Hedged Equity Index, which requires constituents to derive more than 50% of their revenue from outside Europe. The weighted average revenue exposure from Europe in that Index is only 30%. Unhedged Local Exposure Complements Hedged Exporters: There has been a huge amount of interest in currency-hedged eurozone exporters in 2015. The unhedged local recovery basket provides a nice complement both from its unhedged nature and the distinctly different profile of stocks represented in the local recovery Index. Based on the macroeconomic trends discussed in our blog post ” A Recovering Eurozone Economy: Where Should You Position? ,” this local recovery index should also be a focal point for traditional unhedged replacements, as the local economy is showing relative strength within the European economy. Sources Bloomberg, Eurostat and WisdomTree, with data as of 6/30/15. Bloomberg, European Commission, European Central Bank and WisdomTree, with data as of 9/30/15. Bloomberg, FactSet, with data as of 9/30/15. Important Risks Related to this Article Investments focused in Europe increase the impact of events and developments associated with the region, which can adversely affect performance. Jeremy Schwartz, Director of Research As WisdomTree’s Director of Research, Jeremy Schwartz offers timely ideas and timeless wisdom on a bi-monthly basis. Prior to joining WisdomTree, Jeremy was Professor Jeremy Siegel’s head research assistant and helped with the research and writing of Stocks for the Long Run and The Future for Investors. He is also the co-author of the Financial Analysts Journal paper “What Happened to the Original Stocks in the S&P 500?” and the Wall Street Journal article “The Great American Bond Bubble.”